TWI859428B - 顆粒及使用其之製劑 - Google Patents

顆粒及使用其之製劑 Download PDF

Info

Publication number
TWI859428B
TWI859428B TW110108514A TW110108514A TWI859428B TW I859428 B TWI859428 B TW I859428B TW 110108514 A TW110108514 A TW 110108514A TW 110108514 A TW110108514 A TW 110108514A TW I859428 B TWI859428 B TW I859428B
Authority
TW
Taiwan
Prior art keywords
molten component
molten
layer
api
particles
Prior art date
Application number
TW110108514A
Other languages
English (en)
Chinese (zh)
Other versions
TW202200117A (zh
Inventor
吉原尚輝
橋本翔太
木全崚太
Original Assignee
日商澤井製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商澤井製藥股份有限公司 filed Critical 日商澤井製藥股份有限公司
Publication of TW202200117A publication Critical patent/TW202200117A/zh
Application granted granted Critical
Publication of TWI859428B publication Critical patent/TWI859428B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Glanulating (AREA)
TW110108514A 2020-03-11 2021-03-10 顆粒及使用其之製劑 TWI859428B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062988077P 2020-03-11 2020-03-11
US62/988,077 2020-03-11

Publications (2)

Publication Number Publication Date
TW202200117A TW202200117A (zh) 2022-01-01
TWI859428B true TWI859428B (zh) 2024-10-21

Family

ID=77670626

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110108514A TWI859428B (zh) 2020-03-11 2021-03-10 顆粒及使用其之製劑

Country Status (7)

Country Link
US (1) US20230000777A1 (enExample)
EP (1) EP4119130A4 (enExample)
JP (2) JP7467596B2 (enExample)
KR (3) KR20260069752A (enExample)
CN (1) CN115209877B (enExample)
TW (1) TWI859428B (enExample)
WO (1) WO2021182469A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115209877B (zh) * 2020-03-11 2025-02-11 泽井制药株式会社 颗粒和使用该颗粒的制剂
JP7817300B2 (ja) * 2023-02-14 2026-02-18 沢井製薬株式会社 コーティング顆粒、コーティング顆粒を含む製剤及びそれらの製造方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016511223A (ja) * 2012-12-21 2016-04-14 サノフイ フェキソフェナジン高含有固形単位およびその製造法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5290569A (en) * 1990-04-12 1994-03-01 Shionogi & Co., Ltd. Coated composition and its preparation process
ES2096624T3 (es) * 1990-04-12 1997-03-16 Shionogi & Co Composicion revestida y su procedimiento de preparacion.
JPH06256169A (ja) * 1993-02-18 1994-09-13 Amano Pharmaceut Co Ltd 顆粒の製造法
JP3685625B2 (ja) 1998-09-09 2005-08-24 株式会社パウレック 加熱により溶融する物質を用いた粒子加工方法
JP4521654B2 (ja) 2003-04-24 2010-08-11 株式会社ダルトン 造粒物および造粒方法
JP2005075826A (ja) 2003-08-29 2005-03-24 Boehringer Ingelheim Internatl Gmbh 多孔質シリカ担体を含有する徐放性製剤
CN100528233C (zh) * 2003-10-29 2009-08-19 盐野义制药株式会社 不愉快味道改善了的包覆制剂的制造方法
JP2009541337A (ja) * 2006-06-19 2009-11-26 マクニール−ピーピーシー・インコーポレーテツド 活性成分を含有する腸溶性の被覆された粒子
JP2012087073A (ja) * 2010-10-15 2012-05-10 Pharma Polytech:Kk コーティング粒子の製造方法、及び該製造方法で製造されたコーティング粒子
JP2015071542A (ja) 2012-09-10 2015-04-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 固体分散体の製造方法
KR101553348B1 (ko) 2013-12-18 2015-09-15 김예주 주먹밥 포장 시트와 이를 이용한 스틱 주먹밥의 제조 방법
WO2015152190A1 (ja) * 2014-03-31 2015-10-08 富山化学工業株式会社 セファロスポリンエステルを含む粒状固形製剤およびその製造方法
JP2015199721A (ja) 2014-03-31 2015-11-12 富山化学工業株式会社 セファロスポリンエステルを含む粒状固形製剤およびその製造方法
JP6360007B2 (ja) * 2015-06-12 2018-07-18 富士フイルム株式会社 薬物含有粒子の製造方法
KR20170001999A (ko) 2015-06-29 2017-01-06 주식회사 엘지유플러스 셋탑 단말, 셋탑 단말을 위한 어플리케이션, 및 서버의 동작 방법
EP3413937A4 (en) * 2016-02-08 2019-10-30 The Johns Hopkins University COMPOSITIONS AND METHODS OF PREPARING COMPOSITE POLYMER COATINGS ON MEDICAL IMPLANTS AND THEIR USE FOR THE CO-ADMINISTRATION OF SEVERAL ANTIMICROBIAL ACTIVITIES
CN115209877B (zh) * 2020-03-11 2025-02-11 泽井制药株式会社 颗粒和使用该颗粒的制剂

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016511223A (ja) * 2012-12-21 2016-04-14 サノフイ フェキソフェナジン高含有固形単位およびその製造法

Also Published As

Publication number Publication date
CN115209877B (zh) 2025-02-11
JP7467596B2 (ja) 2024-04-15
JPWO2021182469A1 (enExample) 2021-09-16
EP4119130A1 (en) 2023-01-18
WO2021182469A1 (ja) 2021-09-16
KR20260069752A (ko) 2026-05-15
KR20220124747A (ko) 2022-09-14
CN115209877A (zh) 2022-10-18
TW202200117A (zh) 2022-01-01
EP4119130A4 (en) 2024-01-31
JP2024081778A (ja) 2024-06-18
US20230000777A1 (en) 2023-01-05
JP7738697B2 (ja) 2025-09-12
KR20260059682A (ko) 2026-04-30

Similar Documents

Publication Publication Date Title
AU775995B2 (en) Novel preparation and administration form comprising an acid-labile active compound
JP7738697B2 (ja) 顆粒及びそれを用いた製剤
JP2002154954A (ja) トラマドール又はその塩を含む鎮痛剤
KR0168849B1 (ko) 피목 조성물 및 그의 제조방법
CN1148171C (zh) 多单元缓释片剂
TWI850539B (zh) 顆粒及使用其之製劑
JPWO2021182469A5 (enExample)
JP7854897B2 (ja) フィルムコーティング顆粒、それを含む製剤、及びそれらの製造方法
HK40081736A (en) Granules and preparation using same
JP2022046449A (ja) 顆粒、顆粒を含む製剤、顆粒の製造方法、及び顆粒を含む製剤の製造方法
US20230083072A1 (en) Film-coated granule, pharmaceutical preparation containing the same, and manufacturing methods thereof
HK40082230A (en) Granules and preparation using same
MX2007005985A (es) Proceso de fabricacion de nucleos recubiertos por termo-adhesion.